These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34611628)

  • 1. Glioblastoma patient-derived cell-based phenotypic drug screening and identification of possible action mechanisms through proteomic analysis.
    Kim YE; Kim HY; Jung D; Kang D; Nam DH; Nam HJ; Cho H
    STAR Protoc; 2021 Dec; 2(4):100849. PubMed ID: 34611628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
    Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
    J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening.
    Gamboa CM; Jara K; Pamarthy S; Liu L; Aiken R; Xiong Z; Danish S; Sabaawy HE
    STAR Protoc; 2021 Mar; 2(1):100345. PubMed ID: 33665625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy.
    Rose M; Cardon T; Aboulouard S; Hajjaji N; Kobeissy F; Duhamel M; Fournier I; Salzet M
    Front Immunol; 2021; 12():746168. PubMed ID: 34646273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
    Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
    BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening.
    Stackhouse CT; Rowland JR; Shevin RS; Singh R; Gillespie GY; Willey CD
    Cells; 2019 Jul; 8(7):. PubMed ID: 31336733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
    Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
    Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for the Bottom-Up Proteomic Analysis of Mouse Spleen.
    Dowling P; Gargan S; Zweyer M; Henry M; Meleady P; Swandulla D; Ohlendieck K
    STAR Protoc; 2020 Dec; 1(3):100196. PubMed ID: 33377090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MATRIX platform to analyze translation machinery remodeling in glioblastoma cells.
    Ho JJD; Cunningham TA; Krieger JR; Schatz JH; Lee S
    STAR Protoc; 2022 Dec; 3(4):101919. PubMed ID: 36595908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
    Yu KK; Taylor JT; Pathmanaban ON; Youshani AS; Beyit D; Dutko-Gwozdz J; Benson R; Griffiths G; Peers I; Cueppens P; Telfer BA; Williams KJ; McBain C; Kamaly-Asl ID; Bigger BW
    PLoS One; 2018; 13(3):e0193694. PubMed ID: 29499065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.
    Wang L; Zhao H; Cui K; Yao L; Ren M; Hao A; Smollen P; Nie F; Jin G; Liu Q; Wong ST
    Biosci Trends; 2012 Aug; 6(4):192-200. PubMed ID: 23006966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.
    Thaker NG; Zhang F; McDonald PR; Shun TY; Lazo JS; Pollack IF
    Neurosurg Focus; 2010 Jan; 28(1):E4. PubMed ID: 20043719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics.
    Leite DM; Zvar Baskovic B; Civita P; Neto C; Gumbleton M; Pilkington GJ
    FASEB J; 2020 Jan; 34(1):1710-1727. PubMed ID: 31914660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
    Ha W; Sevim-Nalkiran H; Zaman AM; Matsuda K; Khasraw M; Nowak AK; Chung L; Baxter RC; McDonald KL
    Sci Rep; 2019 Feb; 9(1):2905. PubMed ID: 30814573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem mass tag-based thermal proteome profiling for the discovery of drug-protein interactions in cancer cells.
    Johnson FD; Hughes CS; Liu A; Lockwood WW; Morin GB
    STAR Protoc; 2023 Mar; 4(1):102012. PubMed ID: 36856765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.